Invion

Invion Current Liabilities

The Current Liabilities of Invion (IVX.AX) as of Oct 10, 2026 is 2.85 M AUD. In the previous year, Current Liabilities was 1.24 M AUD — a change of 129.92% (higher).

Current Liabilities

2.85 MAUD

YoY

129.92%

Last updated:

Current Liabilities of Invion is 2026 2.85 M AUD. Current Liabilities of Invion was 2025 1.24 M AUD. It decreases by 129.92% higher compared to the previous year.

The Invion Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
837,482.00 AUD
Jan 1, 2020
502,922.00 AUD
Jan 1, 2021
1.21 M AUD
Jan 1, 2022
673,312.00 AUD
Jan 1, 2023
842,625.00 AUD
Jan 1, 2024
1.01 M AUD
Jan 1, 2025
1.24 M AUD
Jan 1, 2026
2.85 M AUD
The Invion Current Liabilities history
YEARCurrent LiabilitiesYoY
2.85 MAUD+129.92%
1.24 MAUD+22.13%
1.01 MAUD+20.32%
842,625.00AUD+25.15%
673,312.00AUD-44.42%
1.21 MAUD+140.87%
502,922.00AUD-39.95%
837,482.00AUD-6.47%
895,389.00AUD-70.20%
3.00 MAUD+371.28%
637,567.00AUD-87.23%
4.99 MAUD+530.23%
792,191.00AUD-1.66%
805,532.00AUD-11.33%
908,445.00AUD-53.16%
1.94 MAUD-72.38%
7.02 MAUD-27.20%
9.64 MAUD+108.39%
4.63 MAUD+22.74%
3.77 MAUD+74.07%
2.17 MAUD-18.38%
2.65 MAUD+183.55%
936,000.00AUD+74.63%
536,000.00AUD-13.27%
618,000.00AUD+122.30%
278,000.00AUD—
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Current Liabilities of Invion is 2.85 M AUD in 2026.

Current Liabilities of Invion changed from 1.24 M AUD to 2.85 M AUD, representing a 129.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Invion since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Invion historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Invion

All Key Metrics — Invion